| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xilong Zhao, William Marszalec, Peter T Toth, Joseph Huang, Jay Z Yeh, Toshio Narahash. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology. vol 51. issue 7-8. 2007-03-09. PMID:17011596. |
since alzheimer's disease is known to be associated with down-regulation of the cholinergic and n-methyl-d-aspartate (nmda) systems, most of these drugs inhibit acetylcholinesterase, potentiate the activity of nicotinic acetylcholine receptors (nachrs), or modulate nmda receptors. |
2007-03-09 |
2023-08-12 |
rat |
| Patrick Lippiello, Sharon R Letchworth, Gregory J Gatto, Vincent M Traina, Merouane Bencheri. Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. Journal of molecular neuroscience : MN. vol 30. issue 1-2. 2007-02-23. PMID:17192610. |
to date, the primary treatments for alzheimer's disease with proven efficacy have been acetylcholinesterase inhibitors that prevent the hydrolysis of acetylcholine (ach) in the synaptic cleft, thereby prolonging its activity. |
2007-02-23 |
2023-08-12 |
Not clear |
| María del Monte-Millán, Esther García-Palomero, Rita Valenzuela, Paola Usán, Celia de Austria, Pilar Muñoz-Ruiz, Laura Rubio, Isabel Dorronsoro, Ana Martínez, Miguel Medin. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. Journal of molecular neuroscience : MN. vol 30. issue 1-2. 2007-02-23. PMID:17192640. |
the therapeutic potential of acetylcholinesterase (ache) inhibitors has been strengthened recently by evidence showing that besides their role in cognitive function, they might contribute to slow down the neurodegeneration in alzheimer's disease (ad) patients. |
2007-02-23 |
2023-08-12 |
Not clear |
| Federica Varsaldi, Gianluca Miglio, Maria Gabriella Scordo, Marja-Liisa Dahl, Laura Maria Villa, Aldo Biolcati, Grazia Lombard. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. European journal of clinical pharmacology. vol 62. issue 9. 2007-02-20. PMID:16845507. |
the aims of this study were to evaluate the impact of the cyp2d6 polymorphism on both the steady-state plasma concentrations (cp) and the clinical outcome of donepezil, a selective acetylcholinesterase inhibitor used in the treatment of alzheimer's disease (ad). |
2007-02-20 |
2023-08-12 |
Not clear |
| Corinne Brühlmann, Andrew Marston, Kurt Hostettmann, Pierre-Alain Carrupt, Bernard Test. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chemistry & biodiversity. vol 1. issue 6. 2007-02-19. PMID:17191882. |
acetylcholinesterase (ache) inhibitors are currently the only approved therapy for the treatment of alzheimer's disease, only a limited number of drugs are commercially available. |
2007-02-19 |
2023-08-12 |
Not clear |
| Malay K Samanta, B Wilson, K Santhi, K P Sampath Kumar, B Sures. Alzheimer disease and its management: a review. American journal of therapeutics. vol 13. issue 6. 2007-02-09. PMID:17122533. |
drugs approved for treating alzheimer disease include acetylcholinesterase inhibitors and n-methyl-d-aspartate (nmda) receptor antagonist. |
2007-02-09 |
2023-08-12 |
Not clear |
| Evan L Thacker, Sebastian Schneeweis. Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients. Drug safety. vol 29. issue 11. 2007-02-08. PMID:17061913. |
acetylcholinesterase inhibitors (acheis), commonly prescribed in alzheimer's disease, may trigger complications of chronic airways disorders. |
2007-02-08 |
2023-08-12 |
Not clear |
| Rafael Blesa, Roger Bullock, Yunsheng He, Howard Bergman, Giuseppe Gambina, Joanne Meyer, Günter Rapatz, Jennifer Nagel, Roger Lan. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and genomics. vol 16. issue 11. 2007-02-06. PMID:17047484. |
a randomized double-blind trial evaluated the efficacy and tolerability of rivastigmine, an inhibitor of acetylcholinesterase (ache) and butyrylcholinesterase (buche), and donepezil, an ache-selective inhibitor, in patients with alzheimer's disease over a 2-year period. |
2007-02-06 |
2023-08-12 |
Not clear |
| José Marco-Contelles, Rafael León, Cristóbal de Los Ríos, Antonio Guglietta, José Terencio, Manuela G López, Antonio G García, Mercedes Villarroy. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. Journal of medicinal chemistry. vol 49. issue 26. 2007-02-02. PMID:17181144. |
novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of alzheimer's disease. |
2007-02-02 |
2023-08-12 |
Not clear |
| Balasubramaniam Easwaramoorthy, Rama Pichika, Daphne Collins, Steven G Potkin, Frances M Leslie, Jogeshwar Mukherje. Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition. Synapse (New York, N.Y.). vol 61. issue 1. 2007-01-26. PMID:17068780. |
acetylcholinesterase inhibitors (achei's) are used to treat alzheimer's disease (ad), and the putative mode of action is to increase acetylcholine (ach) levels. |
2007-01-26 |
2023-08-12 |
rat |
| Hai Yan Zhang, Xi Can Tan. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends in pharmacological sciences. vol 27. issue 12. 2007-01-11. PMID:17056129. |
in recent years, the most common pharmacological treatment for alzheimer's disease (ad) has been acetylcholinesterase (ache) inhibition. |
2007-01-11 |
2023-08-12 |
Not clear |
| Tonmoy Sharma, Catherine Reed, Ingrid Aasen, Veena Kumar. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophrenia research. vol 85. issue 1-3. 2006-12-28. PMID:16797163. |
acetylcholinesterase inhibitors, such as physostigmine and rivastigmine, are considered effective treatments for cognitive decline in alzheimer's disease, where the loss of cholinergic neurons is thought to be responsible for various cognitive deficits. |
2006-12-28 |
2023-08-12 |
Not clear |
| Jana R Cooke, Jose S Loredo, Lianqi Liu, Matthew Marler, Jody Corey-Bloom, Lavinia Fiorentino, Tamara Harrison, Sonia Ancoli-Israe. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs & aging. vol 23. issue 6. 2006-12-22. PMID:16872233. |
acetylcholinesterase inhibitors and sleep architecture in patients with alzheimer's disease. |
2006-12-22 |
2023-08-12 |
Not clear |
| Jana R Cooke, Jose S Loredo, Lianqi Liu, Matthew Marler, Jody Corey-Bloom, Lavinia Fiorentino, Tamara Harrison, Sonia Ancoli-Israe. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs & aging. vol 23. issue 6. 2006-12-22. PMID:16872233. |
studies suggest that some acetylcholinesterase inhibitors (acheis) increase rapid eye movement (rem) sleep and nightmares in patients with alzheimer's disease (ad) but few have studied their effect on other sleep parameters. |
2006-12-22 |
2023-08-12 |
Not clear |
| Yuki Takada-Takatori, Toshiaki Kume, Mitsuhiro Sugimoto, Hiroshi Katsuki, Hachiro Sugimoto, Akinori Akaik. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. vol 51. issue 3. 2006-12-14. PMID:16762377. |
acetylcholinesterase inhibitors used in treatment of alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. |
2006-12-14 |
2023-08-12 |
Not clear |
| Yuki Takada-Takatori, Toshiaki Kume, Mitsuhiro Sugimoto, Hiroshi Katsuki, Hachiro Sugimoto, Akinori Akaik. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. vol 51. issue 3. 2006-12-14. PMID:16762377. |
we show here that donepezil, galanathamine and tacrine, therapeutic acetylcholinesterase inhibitors currently being used for treatment of alzheimer's disease, protect neuronal cells in a time- and concentration-dependent manner from glutamate neurotoxicity that involves apoptosis. |
2006-12-14 |
2023-08-12 |
Not clear |
| Dean M Robinson, Gillian M Keatin. Memantine: a review of its use in Alzheimer's disease. Drugs. vol 66. issue 11. 2006-12-12. PMID:16906789. |
in well designed clinical trials, oral memantine, as monotherapy or in addition to a stable dose of acetylcholinesterase inhibitors, was well tolerated during the treatment of mild to severe alzheimer's disease for up to 52 weeks. |
2006-12-12 |
2023-08-12 |
Not clear |
| Gumpeny Ramachandra Sridhar, Hanuman Thota, Appa Rao Allam, Changalasetty Suresh Babu, Akula Siva Prasad, Ch Divaka. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids in health and disease. vol 5. 2006-12-05. PMID:17096857. |
we found three groups of sequences among a series of 12, with an e-value between 0-12, common to both alzheimer's disease and diabetes: butyrylcholinesterase precursor k allele (np_000046.1), acetylcholinesterase isoform e4-e6 precursor (np_000656.1), and apoptosis-related acetylcholinesterase (1b41|a). |
2006-12-05 |
2023-08-12 |
human |
| Gumpeny Ramachandra Sridhar, Hanuman Thota, Appa Rao Allam, Changalasetty Suresh Babu, Akula Siva Prasad, Ch Divaka. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids in health and disease. vol 5. 2006-12-05. PMID:17096857. |
butyrylcholinesterase and acetylcholinesterase related proteins were found common to both alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism. |
2006-12-05 |
2023-08-12 |
human |
| Hugo Geerts, George T Grossber. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. Journal of clinical pharmacology. vol 46. issue 7 Suppl 1. 2006-11-21. PMID:16809810. |
pharmacology of acetylcholinesterase inhibitors and n-methyl-d-aspartate receptors for combination therapy in the treatment of alzheimer's disease. |
2006-11-21 |
2023-08-12 |
Not clear |